| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5849911 | BRISTOL MYERS SQUIBB | Antivirally active heterocyclic azahexane derivatives |
Jun, 2017
(6 years ago) | |
| US6087383 | BRISTOL MYERS SQUIBB | Bisulfate salt of HIV protease inhibitor |
Dec, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849911 | BRISTOL MYERS SQUIBB | Antivirally active heterocyclic azahexane derivatives |
Jun, 2017
(6 years ago) | |
|
US5849911 (Pediatric) | BRISTOL MYERS SQUIBB | Antivirally active heterocyclic azahexane derivatives |
Dec, 2017
(6 years ago) | |
| US6087383 | BRISTOL MYERS SQUIBB | Bisulfate salt of HIV protease inhibitor |
Dec, 2018
(5 years ago) | |
|
US6087383 (Pediatric) | BRISTOL MYERS SQUIBB | Bisulfate salt of HIV protease inhibitor |
Jun, 2019
(4 years ago) | |
Reyataz is owned by Bristol Myers Squibb.
Reyataz contains Atazanavir Sulfate.
Reyataz has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Reyataz are:
- US5849911
- US5849911*PED
- US6087383
- US6087383*PED
- US5849911
- US6087383
Reyataz was authorised for market use on 20 June, 2003.
Reyataz is available in powder;oral, capsule;oral dosage forms.
Reyataz can be used as method for treating hiv-1 infection.
The generics of Reyataz are possible to be released after 21 June, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-116) | Sep 30, 2011 |
| New Dosing Schedule(D-130) | Feb 04, 2014 |
Drugs and Companies using ATAZANAVIR SULFATE ingredient
Market Authorisation Date: 20 June, 2003
Treatment: Method for treating hiv-1 infection
Dosage: CAPSULE;ORAL; POWDER;ORAL
How can I launch a generic of REYATAZ before it's drug patent expiration?
More Information on Dosage
REYATAZ family patents
